Absci Corp Q3 FY2026 earnings call

Clinical Program Advancements:

• The headline Phase 1/2A trial for pattern hair loss (PHL) is progressing according to plan, with enrollment complete for the highest dose cohort.
• Interim 13-week data for PHL is expected next month (November 2026), showing directional signals of biological activity.
• Full 26-week proof-of-concept (POC) data for PHL is anticipated early in 2027.
• A planned Phase 2 trial for endometriosis ('Storyline') is scheduled to initiate in mid-2027, targeting approximately 150 patients across 10+ countries.

Strategic and Commercial Developments:

• Management highlighted the novel mechanism of ABS-201, which targets the prolactin receptor to potentially stimulate regenerative hair growth in both active and dormant follicles.
• Gary Muehl has been appointed as the first Chief Commercial Officer to build out direct-to-consumer (DTC) infrastructure.
• The company aims to position ABS-201 as a premium therapy combining convenient administration (2-3 injections over six months) with durable efficacy.
• Early-stage pipeline exploration includes non-prolactin targets for metabolism, immunity, healthy aging, and lifestyle optimization, likely developed with a DTC focus.

Financial and Operational Efficiency:

• The clinical development plan is described as capital-efficient relative to the significant market opportunities in PHL and endometriosis.
• Current cash reserves are sufficient to fund operations into the second half of 2028.
• The company emphasizes a strong balance sheet allowing focus on fully-owned programs with outsized commercial potential.

ABSCI is a clinical-stage biotechnology company and does not currently have revenue-generating product segments. The financial performance reflects operating expenses associated with research and development and general administration.

• Research and Development Expenses: $23.6 million for the three months ended September 30, 2026 (compared to $19.2 million in the prior year period). This increase was primarily driven by advancement of internal programs, including direct costs for ABS-201 clinical development, offset by decreased personnel-related costs.
• Selling, General, and Administrative (SG&A) Expenses: $9.0 million for the three months ended September 30, 2026 (compared to $8.4 million in the prior year period). This increase was primarily due to stock-based compensation.
• Cash Position: Cash, cash equivalents, and marketable securities were $173.7 million as of September 30, 2026, compared to $201.1 million as of June 30, 2026.

• Upcoming Data Releases: Interim 13-week PHL data expected in November 2026; full 26-week PHL data expected early 2027.
• Trial Initiation: Phase 2 endometriosis trial initiation targeted for mid-2027.
• Financial Runway: Cash resources ($173.7 million as of Sept 30, 2026) are projected to be sufficient to fund operating plans into the second half of 2028.
• Market Opportunity Estimates: Estimated $25 billion total addressable market in the U.S. for PHL if target area hair count increases by 30-35 hairs/cm²; estimated peak sales of >$4 billion for the endometriosis indication.

• Regulatory and Clinical Uncertainty: Forward-looking statements involve material risks regarding the conduct and timing of trials, regulatory approval, and final labeling.
• Competitive Landscape: Actual addressable markets may differ materially from projections due to competitive products and regulatory decisions.
• Mechanism Validation: Research findings reflect participant responses to hypothetical product profiles, not clinical results for ABS-201.
• Pipeline Risks: Success depends on demonstrating safety, tolerability, and efficacy for ABS-201 and other platform technologies.
• Commercial Execution: Risk that the company fails to successfully build DTC infrastructure or achieve widespread adoption despite positive data.

Q: Analysts asked about the shift in focus towards 'total hair count' (including vellus hairs) rather than just non-vellus counts for the upcoming 13-week data release, and whether this interim data would change the trial conduct. / A: Management clarified that looking at total hair count is not a strategic shift but a holistic view necessary because the novel mechanism supports stem cell niches and keratinocyte proliferation across all follicle types, not just mature non-vellus hairs. They explained that examining vellus hairs provides a complete picture of follicle reactivation, as these may convert to non-vellus hairs later. Regarding trial conduct, they confirmed the interim data will not change the protocol or dosing strategy, as the trial continues to enroll and assess patients according to the original plan.

Q: An analyst questioned how ABS-201's dosing and receptor occupancy compare to competitor HMI-115, specifically regarding why lower human doses might achieve high efficacy compared to higher nominal doses in preclinical studies. / A: Management explained that ABS-201 is designed to maintain greater than 90% prolactin receptor occupancy, leveraging its long half-life of 65 days to allow dosing every 8-12 weeks. In contrast, competitors like HMI-115 have shorter half-lives (approx. 2 weeks), leading to oscillating receptor occupancy that may result in periods where signaling is not fully blocked. Management believes sustained high-level blockade is critical for keeping follicles in the anagen state and preventing miniaturization, which differentiates ABS-201's efficacy profile.

Q: Questions were raised regarding the placebo response expectations for week 13 metrics and the selection of doses (300mg and 1,200mg) for the female pattern hair loss cohorts. / A: Management noted that placebo responses for non-vellous hair count typically show minimal change (plus or minus five hairs) due to the progressive nature of androgenetic alopecia, where natural hair loss and conversion to vellus hairs occur. For the female cohorts, management stated the dose selection was exploratory and based on a 'dose bracketed' approach to gauge efficacy at the low and high ends of the range, rather than being strictly derived from male cohort efficacy data. These female cohorts are open-label without a placebo arm.

Q: Analysts sought clarification on the commercial benchmark for success, specifically what level of hair growth at 26 weeks would drive adoption, and how pigmentation changes are assessed. / A: CFO Zach Jonasson stated that consumer research indicates a target area hair count increase of 30-35 hairs per square centimeter (comparable to high-dose oral minoxidil) would enable rapid market adoption, especially given the convenience of the dosing regimen. Regarding pigmentation, CMO Ransi Somaratne explained that hair darkness is assessed objectively via software analyzing pixel darkness in photographs, not subjectively. While pigmentation changes are not expected to be reported at 13 weeks, they are anticipated to improve over time if the drug recapitulates non-human primate data showing darkening of new hairs.